EUVIMEDEUVIMED entdecken
Crossref

(ID: 109) Implementation of a specialist pharmacy-led medicines optimisation pathway within a proactive multidisciplinary frailty clinic

Kong Hei Chang, Stephanie Hodgson

International Journal of Pharmacy Practice · 05.11.2026 · 34 (Supplement_2) · ii28-ii29

DOI: 10.1093/ijpp/riag145.036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Pharmacy Practice, online erschienen am 06.11.2026. Verfasst von Kong Hei Chang und 1 weiteren Autor:innen. Die Arbeit nennt 2 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Driven by the NHS Long Term Plan’s emphasis on shifting care from hospital-based treatment towards proactive prevention in the community,[1] multidisciplinary frailty hubs are increasingly being developed nationally. These models aim to provide Comprehensive Geriatric Assessment (CGA) for older people living with frailty, supporting earlier optimisation of frailty syndromes, improved quality of life, prevention of crises and reduction in unplanned care. Structured Medication Reviews (SMRs) are recognised as a core component of CGA [2]. However, the specific role, clinical input and optimal structure of specialist frailty pharmacy services within these emerging models remain insufficiently explored. Evaluating this contribution is therefore essential to inform future service development and define pharmacy’s role within proactive frailty hub provision.

Aim

To implement and evaluate a specialist pharmacy-led medicines optimisation pathway within a proactive multidisciplinary frailty clinic setting.

Method

A service evaluation was conducted across 15 weekly multidisciplinary frailty clinics within Same Day Emergency Care at Queens Medical Centre (October 2025–January 2026). The frailty chief pharmacy technicians completed medication histories and initial reviews using a standardised template developed by the frailty pharmacist. Recommendations targeting high-risk prescribing, falls risk, postural hypotension, bone health and deprescribing were clinically validated by the frailty pharmacist and geriatrician before communication to primary care. Patients were followed up after approximately two months to assess implementation. The pilot was conducted as a service evaluation through local governance processes.

Results

75 patients were invited, with 21 attending across 15 clinic sessions (mean age 84 years). 20 of 21 patients (95%) required medicines optimisation interventions. A total of 250 medicines were reviewed. 58 medication-related recommendations were made, comprising 20 deprescribing recommendations (34%), 23 dose adjustments (40%) and 15 medication initiations (26%), equating to an average of 2.9 recommendations per patient. The most common optimisation domains were cardiovascular and postural hypotension management (12 patients, 60%), reduction of medicines associated with falls, sedation or limited benefit (12 patients, 60%), pain management (7 patients, 35%), bone health optimisation (6 patients, 30%) and gastrointestinal protection or bowel management (4 patients, 20%). 19 of the 20 patients (95%) were successfully followed up. Overall, 83% of recommendations had been implemented by primary care at 2 months follow-up, while 17% remained under consideration or had not yet been actioned.

Discussion

This pilot demonstrated successful implementation of a specialist pharmacy-led medicines optimisation pathway within a proactive multidisciplinary frailty service. The high prevalence of medicine-related interventions highlights substantial unmet need in this high-risk population. The structured review process enabled consistent identification of prescribing risks, including fall risk, postural hypotension and inappropriate polypharmacy, while supporting multidisciplinary clinical decision-making. The high rate of recommendation uptake by primary care suggests that clinically validated prescribing interventions were feasible across care settings. Limitations include the small sample size, single-site design and short follow-up period. The project was not designed to assess admission avoidance or long-term clinical outcomes. Findings support wider adoption of structured specialist pharmacy input within proactive frailty pathways. Future evaluation should assess scalability, patient outcomes, healthcare utilisation and cost-effectiveness in larger populations. Keywords Frailty, medicines optimisation, structured medication review, proactive care, multidisciplinary care

Zitieren

APA

Chang, K. H., & Hodgson, S. (2026). (ID: 109) Implementation of a specialist pharmacy-led medicines optimisation pathway within a proactive multidisciplinary frailty clinic. International Journal of Pharmacy Practice, 34(Supplement_2), ii28-ii29. https://doi.org/10.1093/ijpp/riag145.036

Vancouver

Chang KH, Hodgson S. (ID: 109) Implementation of a specialist pharmacy-led medicines optimisation pathway within a proactive multidisciplinary frailty clinic. International Journal of Pharmacy Practice. 2026;34(Supplement_2):ii28-ii29. doi:10.1093/ijpp/riag145.036

BibTeX
@article{Chang2026,
  author = {Chang, Kong Hei and Hodgson, Stephanie},
  title = {(ID: 109) Implementation of a specialist pharmacy-led medicines optimisation pathway within a proactive multidisciplinary frailty clinic},
  journal = {International Journal of Pharmacy Practice},
  year = {2026},
  volume = {34},
  number = {Supplement_2},
  pages = {ii28--ii29},
  doi = {10.1093/ijpp/riag145.036}
}
Kostenlos starten →